Covishield vs Covaxin: India began its Coronavirus vaccination drive today after two vaccines– one by Serum Institute and another by Bharat Biotech– got approval for restricted emergency use earlier. This is a big step in the fight against Coronavirus as nearly three crore high-risk people will be vaccinated against Coronavirus in the first phase of inoculation.
Vaccine sites will either offer Covishield or Covaxin to recipients without giving them an option to choose from the two. However, people can choose to not get vaccinated as inoculation is not mandatory. So far, the government has procured 1.1 crores ‘Covishield’ and 55 lakh ‘Covaxin’ vaccines at a cost of Rs 200 and Rs 206 per dose, respectively.
According to Department of Biotechnology Secretary Renu Swarup, all Indian vaccines will have to be stored at 2-8 degrees Celsius as the logistics have been worked out while considering temperature as a factor.
This vaccine has been developed by the University of Oxford and British-Swedish pharmaceutical company AstraZeneca and manufactured in India by Serum Institute. The frontrunner ‘Covishield’ is stored and transported at a refrigeration temperature of 2-8 degrees Celsius. The vaccine has shown an average efficacy of 70.4 percent in a pooled analysis of interim data from late-stage trials published in The Lancet.
‘Covaxin’ is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a “Vero cell” manufacturing platform by Bharat Biotech. Beneficiaries who will be administered Bharat Biotech’s Covaxin will be paid a compensation in case they suffer adverse events post-vaccination